While the therapy was approved for use in 2014 in the US, Japan was the first country to approve its commercial use in 2008, followed by India in 2010, Europe in 2011, and China in 2013. Because IPF is considered a rare condition, this drug was designated as an ‘orphan drug’ in 2004.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?